SCHEMBL29784205

SCHEMBL29784205

O=c1[nH]cnc2ccc(Cl)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 8/20 1.00
ALDH1A1 P00352 1/20 0.74
PIM1 P11309 2/20 0.64
PIM3 Q86V86 2/20 0.64
CHEK1 O14757 1/20 0.64
AKT1 P31749 1/20 0.64
FLT3 P36888 1/20 0.64
IP6K1 Q92551 7/20 0.58
SLC2A1 P11166 1/20 0.57
PDPK1 O15530 1/20 0.56
CA12 O43570 1/20 0.56
ALOX15 P16050 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CA9 Q16790 1/20 0.56
TNKS2 Q9H2K2 1/20 0.56
IP6K3 Q96PC2 5/20 0.54
IP6K2 Q9UHH9 3/20 0.54
CDC7 O00311 1/20 0.53
DYRK3 O43781 1/20 0.53
IGF1R P08069 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2191006 1.00 PARP1 (1.00) PARP1ALDH1A1PIM1PIM3CHEK1
SCHEMBL29898482 0.85 ALDH1A1 (1.00) PARP1ALDH1A1PIM1PIM3CHEK1
SCHEMBL643424 0.85 ALDH1A1 (1.00) PARP1ALDH1A1PIM1PIM3CHEK1
SCHEMBL8622180 0.81 ACVR1 (0.73) PARP1PIM1PIM3CHEK1AKT1
SCHEMBL11877318 0.78 PARP1 (0.61) PARP1ALDH1A1PIM1PIM3CHEK1
SCHEMBL13718572 0.78 PARP1 (0.63) PARP1ALDH1A1PIM1PIM3CHEK1
SCHEMBL2081677 0.78 PARP1 (1.00) PARP1PIM1PIM3CHEK1AKT1
SCHEMBL2191067 0.78 PARP1 (1.00) PARP1ALDH1A1PIM1PIM3CHEK1
SCHEMBL216176 0.78 PARP1 (1.00) PARP1ALDH1A1PIM1PIM3CHEK1
SCHEMBL642178 0.78 PARP1 (1.00) PARP1PIM1PIM3CHEK1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112239464-B Quinazoline-4 (3H) -ketone derivative containing 1,3, 4-oxadiazole, preparation method and application 南京农业大学 2022-09-16 CN claimed
CN-119462526-A Method for synthesizing quinazolinone compound by catalytic cyclization of titanocene dichloride 陕西师范大学 2025-02-18 CN disclosed
CN-118996447-A Phosphine-oxide substituted quinoxaline quinazolinone compound, preparation method and application thereof 南阳师范学院 2024-11-22 CN disclosed
CN-115003658-B Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency 森特萨制药(英国)有限公司 2024-07-23 CN disclosed
CN-112105419-B Condensed ring compound 豪夫迈·罗氏有限公司 2024-03-29 CN disclosed
CN-115260164-B Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs 杭州星鳌生物科技有限公司 2024-03-26 CN disclosed
CN-117157285-A Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors 阿尔麦克探索有限公司 2023-12-01 CN disclosed
CN-116804001-A Quinazolinone derivative containing pyridinium and preparation method and application thereof 江苏海洋大学 2023-09-26 CN disclosed
CN-113637011-B Myricetin derivative containing quinazoline-4 (3H) -ketone and preparation method and application thereof 贵州大学 2023-03-31 CN disclosed
WO-2022263829-A1 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY Z Factor Limited (GB) 2022-12-22 WO disclosed
WO-2022233253-A1 METHOD FOR PREPARING NEW 4(3H)-QUINAZOLINONE ANALOG, STRUCTURAL COMPOSITION THEREOF, AND USE THEREOF IN ANTITUMOR DRUGS 杭州星鳌生物科技有限公司 2022-11-10 WO disclosed
CN-115260164-A Preparation method and structural composition of novel 4 (3H) -quinazolinone analogue and application of analogue in antitumor drugs 杭州星鳌生物科技有限公司 2022-11-01 CN disclosed
EP-4073043-A1 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY Z Factor Limited (GB) 2022-10-19 EP disclosed
CN-112239464-B Quinazoline-4 (3H) -ketone derivative containing 1,3, 4-oxadiazole, preparation method and application 南京农业大学 2022-09-16 CN disclosed
CN-110981817-B Quinazoline amide compound and application thereof 青岛科技大学 2022-09-16 CN disclosed
US-11390610-B2 Piperazine derivatives as MAGL inhibitors HOFFMANN-LA ROCHE INC. (US) 2022-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11390610-B2 Piperazine derivatives as MAGL inhibitors MAGI3, PYM1, MAG PARP1 3907/4885ALDH1A1 3240/4885PIM1 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.